A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline–based therapy. We aimed to evaluate the prognostic implications of serum β-2 microglobulin (β2M) in the context of PINK and proposed a new prognostic model.Materials and Methods A total of 138 patients who were newly diagnosed with ENKTL and treated with non-anthracycline-based chemotherapy were identified. The cut-off value of high serum β2M was calculated by maximal-chi square methods (4.1 mg/L). A new prognostic model incorporating serum β2M into PINK was proposed and validated in an independent validation cohort (n=88).Results The patients’ median age was 53.5 years (range, 19 to 80 years). Patients with high serum β2M levels had significantly worse overall survival (OS) and progression-free survival (PFS). In multivariate analysis, high serum β2M was an independent adverse prognostic factor for OS. A new PINK-B (Prognostic Index for Natural Killer Lymphoma-serum β-2 microglobulin) model stratifiedpatients into three groups with distinct OS and PFS in the training cohort (3-year OS, 84.1% [95% confidence interval, 75.1 to 94.2], 46.8% [36.1 to 60.8] and 17.6% [6.3 to 49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4 to 83.8], 35.9% [25.9 to 49.8], and 7.35% [1.1 to 46.7] for the low-, intermediate-, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort.Conclusion Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into daily clinical practice.
Abstract
Purpose Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline–based therapy. We aimed to evaluate the prognostic implications of serum β-2 microglobulin (β2M) in the context of PINK and proposed a new prognostic model.Materials and Methods A total of 138 patients who were newly diagnosed with ENKTL and treated with non-anthracycline-based chemotherapy were identified. The cut-off value of high serum β2M was calculated by maximal-chi square methods (4.1 mg/L). A new prognostic model incorporating serum β2M into PINK was proposed and validated in an independent validation cohort (n=88).Results The patients’ median age was 53.5 years (range, 19 to 80 years). Patients with high serum β2M levels had significantly worse overall survival (OS) and progression-free survival (PFS). In multivariate analysis, high serum β2M was an independent adverse prognostic factor for OS. A new PINK-B (Prognostic Index for Natural Killer Lymphoma-serum β-2 microglobulin) model stratifiedpatients into three groups with distinct OS and PFS in the training cohort (3-year OS, 84.1% [95% confidence interval, 75.1 to 94.2], 46.8% [36.1 to 60.8] and 17.6% [6.3 to 49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4 to 83.8], 35.9% [25.9 to 49.8], and 7.35% [1.1 to 46.7] for the low-, intermediate-, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort.Conclusion Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into daily clinical practice.
참고문헌 (24)
- Haverkos BM, "Extranodal NK", T cell lymphoma, nasal type(ENKTL-NT) : an update on epidemiology, clinical presentation, and natural history in North American and European cases, 2016, pp.11, 514~527
- Wang H, "NK-", T-cell lymphomas, 2021, pp.35, 2460~2468
- Yamaguchi M, "Advances in the treatment of extranodal NK", T-cell lymphoma, nasal type, 2018, pp.131, 2528~2540
- Tse E, "How I treat NK", T-cell lymphomas, 2013, pp.121, 4997~5005
- Lim SH, "Beyond first-line non-anthracycline-based chemotherapy for extranodal NK", T-cell lymphoma : clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease, 2017, pp.28, 2199~2205
- Kim SJ, "A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment : a multicentre, retrospective analysis", Lancet Oncol, 17, pp.389~400 (2016)
- Dasgupta A, "Clinical chemistry, immunology and laboratory quality control", pp.229~247 (2014), Elsevier
- 유창훈, "Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor", Blood Research, 49(3), pp.148~153 (2014), 대한혈액학회
- Yoo C, "Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer", T cell lymphoma, 2014, pp.93, 995~1000
- Li ZM, "Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK", T-cell lymphoma, 2012, pp.91, 1265~1270
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- "Instruction for beta 2 microglobulin assay" (2022)[URL]
- Miller R, "Maximally selected chi square statistics", Biometrics, 38, pp.1011~1016 (1982)
- Greipp PR, "International staging system for multiple mye-loma", J Clin Oncol, 23, pp.3412~3420 (2005)
- International CLL-IPI Working Group, "An international prognostic index for patients with chronic lymphocytic leukaemia(CLL-IPI) : a meta-analysis of individual patient data", Lancet Oncol, 17, pp.779~790 (2016)
- Federico M, "Follicular lymphoma international prognostic index 2 : a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project", J Clin Oncol, 27, pp.4555~4562 (2009)
- Kim HD, "A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum beta2-microglobulin levels", Br J Haematol, 193, pp.307~315 (2021)
- Shang Y, "B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma", Sci Rep, 8, pp.12907~ (2018)
- Yamaguchi M, "Treatments and outcomes of patients with extranodal natural killer", T-cell lymphoma diagnosed between 2000 and 2013 : a cooperative study in Japan, 2017, pp.35, 32~39
- Kim SJ, "Treatment of localized extranodal NK", T cell lymphoma, nasal type : a systematic review, 2018, pp.11, 140~
- Ha JY, "Superiority of Epstein-Barr virus DNA in the plasma over whole blood for prognostication of extranodal NK", T cell lymphoma, 2020, pp.10, 594692~
- Chen R, "Prognostic implications of circulating Epstein-Barr virus DNA for extranodal natural killer", T-cell lymphoma, nasal type : a meta-analysis, 2018, pp.10, 2183~2192
- Tan KM, "A clinicohaematological prognostic model for nasal-type natural killer", T-cell lymphoma : a multicenter study, 2019, pp.9, 14961~
- Lee J, "Extranodal natural killer T-cell lymphoma, nasal-type : a prognostic model from a retrospective multicenter study", J Clin Oncol, 24, pp.612~618 (2006)